An overview of novel corona virus 2019-NCOV and their clinical and immune responses

Abstract

The novel virus such as corona virus 2019 is the main cause of the disease that is declared by the WHO (World Health Origination). Some other virus similar to this virus were also discovered in initial year of 21th century such as SARS-CoV in 2003, HCoV NL63 in 2004, HKU1 in 2005, MERS-CoV in 2012, and SARS-CoV-2 in 2019. The first few cases of covid-19 were detected from direct contact to the infected animal to human which is also called as animal to human transmission. Due to direct exposure of this virus to infected animals the human to human transmission of the virus is as well possible, which is also likely to be consider and measured as core form of transmission. According to the reports of WHO by 26 February 2020, patients suffering from COVID-19 reduced gradually in China but rapidly increased in countries like Italy, Iran and South Korea. The infection caused by the COVID 19 is detected by look-ing at the symptoms and it ultimately confirmed by the reverse transcription polymerase chain reaction (rRT-PCR) of infected secretions with 71% sensi-tivity and computed tomography scan with 98%. The antimalarial medicate, hydroxychloroquine, is authorized for the chemoprophylaxis and treatment of intestinal sickness and as a disease changing antirheumatic drugs. Pharmaco-logical demonstrating dependent on observed drug absorptions and in vitro drug testing propose that prophylaxis with hydroxychloroquine at affirmed portions could anticipate SARS-CoV-2 contamination and improve viral shed-ding. Clinical preliminaries of hydroxychloroquine treatment for COVID-19 pneumonia are in progress in China (NCT04261517 and NCT04307693).